SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddy's to launch Molflu at Rs 35 per capsule for COVID treatment

05 Jan 2022 Evaluate

Dr Reddy's Laboratories is planning to launch Molflu (Molnupiravir) at Rs 35 per capsule to treat COVID-19 in the country. With 10 capsules per strip, the total course of 40 capsules over 5 days would cost Rs 1,400, making it among the most affordable treatment options available to patients. Molflu will be manufactured at a USFDA-approved facility, and the drug maker has made adequate capacity preparations to ensure that it is able to help patients in need.  

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1238.75 3.35 (0.27%)
20-Apr-2026 12:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.50
Dr. Reddys Lab 1238.75
Cipla 1240.00
Zydus Lifesciences 942.95
Lupin 2336.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×